AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

In allergen-driven models of atopic dermatitis, subcutaneous (SQ) administration of ‘1104 demonstrated comparable performance to intravenous administration (IV) In multiple preclinical models ...

Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking ...

AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming ...

Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...

H.C. Wainwright downgraded AnaptysBio (ANAB) to Neutral from Buy with a price target of $19, down from $52, after the company announced topline ...

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...

Atopic dermatitis was associated with a significantly increased bipolar disorder risk among a large population-based cohort in the US.

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...

Diagnosing and managing feline atopic dermatitis (FAD) can be difficult for clients, and can even be a challenge for ...